Jupiter Neurosciences Secures 3-Month Extension on Convertible Note Payments
JUNS is trading near its 52-week low of $0.48 (8.3% above the low) on light trading volume (0.1× avg).
Summary
Jupiter Neurosciences amended its $6.0 million convertible notes, delaying monthly payments by three months and revising the payment schedule, providing immediate liquidity relief.
Key Events · Financing and Capital Events · JUNS
-
Convertible Note Amendment
The company entered into an Omnibus Amendment with YA II PN, LTD, modifying the terms of its $6.0 million convertible promissory notes.
-
Payment Extension Granted
Monthly installment payments for the convertible notes will now commence on April 1, 2026, an extension of approximately three months from the previous schedule.
-
Revised Payment Schedule
The amendment introduces a variable payment schedule for the notes and updates provisions related to Advance Notices under the Standby Equity Purchase Agreement (SEPA).
-
Enhanced Financial Flexibility
This extension provides Jupiter Neurosciences with additional time and flexibility in managing its cash flow and debt obligations.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences, a life sciences company, has amended its existing $6.0 million convertible promissory notes with Yorkville, pushing back the start of monthly installment payments by approximately three months to April 1, 2026. This provides the company with crucial short-term financial flexibility and extends its cash runway, which is particularly important for a small-cap biotech firm managing development costs. The amendment also introduces a variable payment schedule and clarifies how proceeds from future equity sales under the Standby Equity Purchase Agreement (SEPA) will be allocated, with 50% potentially used to prepay future installments.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $0.48 to $3.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.